4//SEC Filing
Pfizer Ventures (US) LLC 4
Accession 0000078003-20-000023
CIK 0001672619other
Filed
Mar 15, 8:00 PM ET
Accepted
Mar 16, 7:15 PM ET
Size
19.8 KB
Accession
0000078003-20-000023
Insider Transaction Report
Form 4
IMARA Inc.IMRA
PFIZER INC
10% Owner
Transactions
- Purchase
Common Stock
2020-03-16$16.00/sh+312,500$5,000,000→ 1,481,719 total(indirect: By LLC) - Conversion
Series A Preferred Stock
2020-03-16−5,470,492→ 0 total(indirect: By LLC)→ Common Stock (868,467 underlying) - Conversion
Series B Preferred Stock
2020-03-16−1,894,444→ 0 total(indirect: By LLC)→ Common Stock (300,752 underlying) - Conversion
Common Stock
2020-03-16+300,752→ 1,169,219 total(indirect: By LLC) - Conversion
Series Seed Preferred Stock
2020-03-16−478,749→ 0 total→ Common Stock (76,003 underlying) - Conversion
Common Stock
2020-03-16+76,003→ 76,003 total - Conversion
Common Stock
2020-03-16+868,467→ 868,467 total(indirect: By LLC)
Pfizer Ventures (US) LLC
10% Owner
Transactions
- Conversion
Common Stock
2020-03-16+300,752→ 1,169,219 total(indirect: By LLC) - Purchase
Common Stock
2020-03-16$16.00/sh+312,500$5,000,000→ 1,481,719 total(indirect: By LLC) - Conversion
Series Seed Preferred Stock
2020-03-16−478,749→ 0 total→ Common Stock (76,003 underlying) - Conversion
Series B Preferred Stock
2020-03-16−1,894,444→ 0 total(indirect: By LLC)→ Common Stock (300,752 underlying) - Conversion
Common Stock
2020-03-16+76,003→ 76,003 total - Conversion
Series A Preferred Stock
2020-03-16−5,470,492→ 0 total(indirect: By LLC)→ Common Stock (868,467 underlying) - Conversion
Common Stock
2020-03-16+868,467→ 868,467 total(indirect: By LLC)
Footnotes (5)
- [F1]On March 16, 2020, each share of Series Seed Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series Seed Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series Seed Preferred Stock had no expiration date.
- [F2]On March 16, 2020, each share of Series A Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series A Preferred Stock had no expiration date.
- [F3]On March 16, 2020, the Issuer's Series B Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series B Preferred Stock had no expiration date.
- [F4]Each reporting person disclaims ownership of securities held by each other reporting person, except to the extent of its respective pecuniary interest therein.
- [F5]Pfizer Ventures (US) LLC purchased 312,500 additional shares of common stock in the Issuer's initial public offering at the initial public offering price of $16.00 per share.
Documents
Issuer
IMARA Inc.
CIK 0001672619
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001776087
Filing Metadata
- Form type
- 4
- Filed
- Mar 15, 8:00 PM ET
- Accepted
- Mar 16, 7:15 PM ET
- Size
- 19.8 KB